학술논문
Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)
Document Type
Article
Author
Bolaños-Meade, J.; Jones, R.J.; Reshef, R.; Fraser, R.; Fei, M.; Logan, B.R.; Hari, P.; Horowitz, M.M.; Pasquini, M.C.; Abhyankar, S.; Al-Kadhimi, Z.; Alousi, A.M.; Antin, J.H.; Koreth, J.; Arai, S.; Bickett, K.; Wu, J.; Chen, Y.-B.; Damon, L.E.; Efebera, Y.A.; Geller, N.L.; Giralt, S.A.; Holtan, S.G.; Weisdorf, D.J.; MacMillan, M.L.; Jacobsohn, D.A.; Liesveld, J.L.; Mielcarek, M.; Noel, P.; Pidala, J.; Porter, D.L.; Pusic, I.; Sobecks, R.; Solomon, S.R.
Source
In: The Lancet Haematology . (The Lancet Haematology, March 2019, 6(3):e132-e143)
Subject
Language
English
ISSN
23523026